Objectif
Only few patients respond to tumor treatment as desired. Treatment heavily relies on host tumor interactions, including exploiting the host immune response against the tumor. The underlying mechanisms of host tumor interaction are largely unknown, guidance on specific intervention is missing. To improve outcome, better understanding of tumor-host interaction is needed. Large numbers of molecular snapshots will provide increased phenotyping coverage and better represent tumor-host evolution over time. In an innovative approach, MULTIR aims at investigating not a single tumor entity, but at compiling data from melanoma, lung and bladder cancer (most drugs target specific molecular features, irrespective of the tumor origin) to identify with high power the critical elements in the tumor-host interaction responsible for therapy response. In a multi-disciplinary approach involving leading clinicians, immunologists, experts in omics, digital technologies, social sciences and patient representatives from 10 EU countries and beyond, and an extensive outreach plan to ensure rapid transfer of MULTIR output to society, MULTIR combines existing multi-layer (epidemiological, genetic, clinical, pathologic, imaging, molecular) data from major studies on these tumors, using AI-based approaches to unveil functional modules regulating tumor-host interactions followed by validation of findings in models and synthetic patients. Harmonization with major EU initiatives will maximize use of European resources. Impact on all scientific, technological and societal levels is expected, including increased understanding of tumor-host interactions, generation of a unique resource of harmonized data on three major cancer types available to the community in compliance to the legal and ethics framework, boost of drug discovery, and an AI-based predictor for treatment response. MULTIR outreach plan includes policymakers and regulators, to support prompt assessment and uptake into the health systems.
This action is part of the Cancer Mission cluster of projects on “Understanding (tumour-host interactions)”.
Champ scientifique
Mots‑clés
Programme(s)
- HORIZON.2.1 - Health Main Programme
Régime de financement
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinateur
75654 Paris
France
Voir sur la carte
Participants (14)
44093 Nantes
Voir sur la carte
45147 Essen
Voir sur la carte
30659 Hannover
Voir sur la carte
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.
115 27 Athina
Voir sur la carte
6525 GA Nijmegen
Voir sur la carte
4 Dublin
Voir sur la carte
10000 ZAGREB
Voir sur la carte
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.
8000 Aarhus C
Voir sur la carte
1090 Wien
Voir sur la carte
114 71 ATHENS
Voir sur la carte
153 44 GERAKAS ATTIKI
Voir sur la carte
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.
27600 SARRIA
Voir sur la carte
0456 Oslo
Voir sur la carte
75006 Paris
Voir sur la carte
Partenaires (2)
8006 Zurich
Voir sur la carte
H3A0G4 Montreal
Voir sur la carte